Citius Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Feb 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2023 · Filed Feb 14, 2024
CTXR$0.53-3.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| 2.1+ | Agreement and Plan of Merger and Reorganization, dated as of October 23, 2023, by and among Citius Pharmaceuticals, Inc., Citius Oncology, Inc., TenX Keane Acquisition, and TenX Merger Sub, Inc. (incorporated herein by reference to Exhibit 2.1 to the Current Report on Form 8-K filed on October 24, 2023). |
| 10.1+ | Sponsor Support Agreement, dated as of October 23, 2023, by and among 10XYZ Holdings LP, TenX Keane Acquisition, Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on October 24, 2023). |
| 10.2 | Form of Amended and Restated Registration Rights Agreement (incorporated herein by reference to Exhibit 10.2 to the Current Report on Form 8-K filed on October 24, 2023). |
| 10.3+ | Form of Amended and Restated Shared Services Agreement (incorporated herein by reference to Exhibit 10.3 to the Current Report on Form 8-K filed on October 24, 2023). |
| 31.1 | Certification of the Principal Executive Officer pursuant to Exchange Act Rule 13a-14(a).* |
| 31.2 | Certification of the Principal Financial Officer pursuant to Exchange Act Rule 13a-14(a).* |
| 32.1 | Certification of the Principal Executive and Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002.* |
| EX-101.INS | Inline XBRL Instance Document* |
| EX-101.SCH | Inline XBRL Taxonomy Extension Schema Document* |
| EX-101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document* |
| EX-101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document* |
| EX-101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document* |
| EX-101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document* |
| EX-104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
| * | Filed herewith. |
|---|---|
| + | Certain of the exhibits and schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(b)(2) or 601(a)(5), as applicable. Citius Pharma agrees to furnish supplementally a copy of all omitted exhibits and schedules to the SEC upon its request. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.